相似文献
1
Targeting AML-associated FLT3 mutations with a type I kinase inhibitor.
J Clin Invest. 2020 Apr 1;130(4):2017-2023. doi: 10.1172/JCI127907.
2
Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.
Cancer. 2018 Jan 15;124(2):306-314. doi: 10.1002/cncr.31038. Epub 2017 Sep 28.
3
FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Minerva Med. 2020 Oct;111(5):427-442. doi: 10.23736/S0026-4806.20.06989-X. Epub 2020 Sep 21.
4
Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors.
Biochem Pharmacol. 2021 Jan;183:114348. doi: 10.1016/j.bcp.2020.114348. Epub 2020 Nov 23.
5
The Future of Targeting FLT3 Activation in AML.
Curr Hematol Malig Rep. 2017 Jun;12(3):153-167. doi: 10.1007/s11899-017-0381-2.
6
Discovery and characterization of novel mutant FLT3 kinase inhibitors.
Mol Cancer Ther. 2010 Sep;9(9):2468-77. doi: 10.1158/1535-7163.MCT-10-0232. Epub 2010 Aug 31.
7
Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia.
Hematology. 2019 Dec;24(1):651-660. doi: 10.1080/16078454.2019.1666219.
8
FLT3 signaling and the development of inhibitors that target FLT3 kinase activity.
Crit Rev Oncog. 2012;17(2):199-209. doi: 10.1615/critrevoncog.v17.i2.50.
9
Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors.
Expert Rev Anticancer Ther. 2019 Mar;19(3):273-286. doi: 10.1080/14737140.2019.1573679. Epub 2019 Feb 6.
10
Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice.
EBioMedicine. 2019 Feb;40:231-239. doi: 10.1016/j.ebiom.2019.01.012. Epub 2019 Jan 25.
引用本文的文献
1
Optimization of IRAK1/4/pan-FLT3 kinase inhibitors as treatments for acute myeloid leukemia.
Bioorg Med Chem Lett. 2025 Aug 5;129:130355. doi: 10.1016/j.bmcl.2025.130355.
2
Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Myeloid Leukemias.
Cureus. 2025 Jun 18;17(6):e86322. doi: 10.7759/cureus.86322. eCollection 2025 Jun.
3
Microbial metabolite drives ageing-related clonal haematopoiesis via ALPK1.
Nature. 2025 Apr 23. doi: 10.1038/s41586-025-08938-8.
4
Discovery of IRAK1/4/pan-FLT3 Kinase Inhibitors as Treatments for Acute Myeloid Leukemia.
ACS Med Chem Lett. 2024 Oct 23;15(11):1843-1851. doi: 10.1021/acsmedchemlett.4c00269. eCollection 2024 Nov 14.
5
Characteristics and Outcome of FLT3-ITD-Positive Pediatric Acute Myeloid Leukemia-Experience of Polish Pediatric Leukemia and Lymphoma Study Group from 2005 to 2022.
Cancers (Basel). 2023 Sep 14;15(18):4557. doi: 10.3390/cancers15184557.
6
Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML.
Blood. 2023 Sep 14;142(11):989-1007. doi: 10.1182/blood.2022018718.
7
Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammation.
Haematologica. 2023 Oct 1;108(10):2715-2729. doi: 10.3324/haematol.2022.282349.
8
Overcoming Resistance: FLT3 Inhibitors Past, Present, Future and the Challenge of Cure.
Cancers (Basel). 2022 Sep 2;14(17):4315. doi: 10.3390/cancers14174315.
9
Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AML.
Blood Adv. 2023 Apr 25;7(8):1460-1476. doi: 10.1182/bloodadvances.2022007486.
10
Targeted Therapies in Cancer: To Be or Not to Be, Selective.
Biomedicines. 2021 Nov 1;9(11):1591. doi: 10.3390/biomedicines9111591.
本文引用的文献
1
Overcoming adaptive therapy resistance in AML by targeting immune response pathways.
Sci Transl Med. 2019 Sep 4;11(508). doi: 10.1126/scitranslmed.aaw8828.
2
Quizartinib tested in patients with high-risk AML.
Nat Rev Clin Oncol. 2018 Sep;15(9):532. doi: 10.1038/s41571-018-0061-8.
3
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Lancet Oncol. 2017 Aug;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3. Epub 2017 Jun 20.
4
FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.
Mol Cancer Ther. 2017 Jun;16(6):991-1001. doi: 10.1158/1535-7163.MCT-16-0876.
5
Midostaurin approved for FLT3-mutated AML.
Blood. 2017 Jun 29;129(26):3403-3406. doi: 10.1182/blood-2017-05-782292. Epub 2017 May 25.
6
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
Invest New Drugs. 2017 Oct;35(5):556-565. doi: 10.1007/s10637-017-0470-z. Epub 2017 May 17.
7
Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis.
Blood. 2017 Jul 6;130(1):48-58. doi: 10.1182/blood-2016-04-711820. Epub 2017 May 10.
8
Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.
Blood. 2017 Jan 12;129(2):257-260. doi: 10.1182/blood-2016-10-745133. Epub 2016 Dec 1.
9
How I treat FLT3-mutated AML.
Blood. 2017 Feb 2;129(5):565-571. doi: 10.1182/blood-2016-09-693648. Epub 2016 Nov 21.
10
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors.
Leukemia. 2015 Dec;29(12):2390-2. doi: 10.1038/leu.2015.165. Epub 2015 Jun 25.
Zotero 插件